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Background: Based on the increased pre-eclampsia and HIV antenatal incidence in South Africa, we determined the angiogenic 
profiles due to its mechanistic link in preeclampsia development, throughout uncomplicated pregnancies in HIV positive and 
negative women.
Objective: To determine the angiogenic profiles throughout  uncomplicated pregnancies in HIV positive and HIV negative 
women. We explored possible correlations between angiogenic serum levels and selected maternal characteristics (HIV status, 
gestational age, maternal factors, and pregnancy outcomes).
Method: This study was conducted at a primary health care facility in Durban, South Africa. Forty-six pregnant women aged 
18-45 years, were enrolled at 10-20, 22-30 and 32-38 weeks’ gestation, respectively through convenient sampling. Serum samples 
were collected and quantitatively evaluated using ELISAs. Clinical and epidemiological data were analysed using STATA (version 
14). A probability level of  p < 0.05 was considered statistically significant.
Results: Of  those enrolled, 28.3% were nulliparous, 82% were HIV positive and none developed pre-eclampsia. Systolic and 
diastolic blood pressure increased slightly throughout pregnancy. Fluctuating angiogenic and anti-angiogenic levels were demon-
strated during pregnancy.
Conclusion: This study contributes to the current angiogenic knowledge in normotensive pregnancies, and may assist as a 
reference range against which these factors may be compared in HIV complicated pregnancies.
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Introduction
Despite the significant decrease in maternal morbidity and 
mortality worldwide, the WHO 2015 estimates highlight 
that approximately 303, 000 maternal deaths will occur by 
2015, with a maternal mortality rate of  216 per 100,000 
live births during pregnancy, at delivery or postnatally, 
most cases occurring  in low- and middle-income coun-
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tries1.  Suboptimal antenatal care in South Africa is linked 
with poorer uptake of  Human Immunodeficiency Virus 
(HIV) testing and adverse maternal and birth outcomes2,3. 
In developing and resource constrained countries such as 
South Africa, HIV is responsible for an estimated 40% of  
all maternal deaths4. The antenatal HIV prevalence of  ap-
proximately 40% is the highest in KwaZulu-Natal, South 
Africa5.  To date, the most effective intervention used 
to prevent  mother-to-child-transmission is the use of  
highly active antiretroviral treatment (HAART)4, which 
alters maternal immunological responses thus improving 
maternal and perinatal outcomes4,6. Despite the obvious 
benefits of  HAART in pregnant women, the rates of  ad-
verse birth outcomes is still reportedly higher in HIV pos-
itive women on HAART than HIV-uninfected women6,7. 
Moreover, earlier studies have shown inconsistencies in 
the angiogenic expression in women on anti retrovirals in 
comparison to HIV uninfected women8,9, whilst a more 
recent South African study suggest that HIV possibly 
jeopardizes vascular perfusion during pregnancy, partic-
ularly placental development10.  
 
Fetal development relies on adequate placental growth 
which is dependent on branching and non branching 
angiogenesis11,12. Branching angiogenesis occurs during 
the first 24 weeks of  pregnancy, under relative hypoxic 
conditons, in contrast to third trimester non branching 
angiogenesis12. Placental trophoblasts secrete angiogenic 
placental growth factor (PlGF) and vascular endothelial 
growth factor (VEGF) into the maternal vasculature, sup-
porting endothelial proliferation and survival, and arterial 
remodeling13,14. The bioavailability of  both VEGF and 
PlGF is controlled by the anti-angiogenic factor soluble 
fms-like tyrosine kinase-1 (sFlt-1), which is a splice variant 
of  the VEGF receptor15,16. Likewise, increased circulating 
levels of  soluble endoglin (sEng) was also demonstrated 
and implicated in PE development17. Moreover, this pla-
cental derived protein competes with endoglin to bind 
to circulating transforming growth factor beta (TGF-β), 
thus weakening its signaling17. Walshe et al.18 suggests 
that the impaired signaling of  VEGF and/or TGF-β 
pathways may contribute to the endothelial dysnfunction 
that characterizes PE development. This disrupted angio-
genic expression is linked with fetal growth restriction19, 
preterm delivery20 as well as hypertensive disorders of  
pregnancy (HDP), including preeclampsia (PE)21, coro-
nary artery disease22, heart failure and maternal vascular 
malperfusion10.  It is possible that the altered placental 
perfusion contributes systemic alterations in the circulat-
ing expression of  angiogenic factors23. 
 
Pregnancy induced hypertensive disorders like PE are be-
lieved to occur in response to an immune-induced pla-
cental alteration evoked possibly by HIV and HAART 
mediated immune disturbances10. PE is characterized by 
increased circulating sFlt-1 levels, which inhibit angiogen-
ic signaling and subsequently induce endothelial dysfunc-
tion24. Placental delivery is no longer an option for PE 
resolution since epidemiological evidence confirms the 
onset of  various long-term cardiovascular disorders, long 
after the dissolution of  preeclampsia symptoms21,25. De-
spite the improved understanding of  PE, delayed child-
bearing combined with maternal body mass index (BMI), 
maternal age, and parity, may be correlated with angio-
genic balance even in uncomplicated pregnancies26,27. 
Earlier studies demonstrates the clinical role of  mater-
nal PlGF and sFlt-1 levels as valuable predictors of  pre-
eclampsia development and its associated consequences 
in both mother and fetus28,29, thereby supporting their 
increased use in both maternal and fetal investigations 
because of  its link with placental development30. Others 
have also recommended that evaluating maternal con-
centrations of  both sFlt-1 and sEng may be helpful in 
the prognosis of  pregnancy complications such as pre-
eclampsia and intrauterine growth restriction19,31,32. Whilst 
we together with several others, have evaluated the an-
giogenic profiles in normal pregnancies as a means of  
comparing them with complicated pregnancies, the inten-
tion of  such data was not intended at instituting reference 
values28,33,34.
 
We therefore aimed to determined the angiogenic and 
anti-angiogenic profiles through three gestational periods 
from uncomplicated pregnancies in HIV positive (HIV 
+ve) and HIV negative (HIV -ve) women. We further 
explored  possible correlations between serum levels of  
these analytes and selected maternal characteristics (HIV 
status, gestational age, maternal factors, and pregnancy 
outcomes). Since there was limited South African data, 
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we intended to  contribute to the current knowledge on 
serum levels of  sFlt-1, PlGF and soluble endoglin (sEng).
 
Methods
This was a prospective study which was nested within a 
birth cohort study.  It was conducted at a primary health 
care (PHC) facility in Durban, South Africa between 2015 
and 2016. Antenatal care in South Africa is usually initi-
ated before 20 weeks of  gestation as prescribed by the 
National Department of  Health35. Only participants who 
presented for their first antenatal visit, prior to  20 weeks 
gestation and who consented to blood collection at the 
3 gestational periods were included in the study, which 
resulted in a final convenient sample number of  46.  Par-
ticipants could not be followed until delivery, since PHC 
facilities feed into various public health hospitals, result-
ing in logistical challenges in retaining all participants 
until delivery. Adolescent pregnancies (<18 yrs), women 
presenting with chronic diabetes, chronic hypertension, 
gestational diabetes, connective tissue disorder, cardiac 
disease, sickle cell disease, anti-phospholipid antibody 
syndrome, chorioamnionitis, unknown HIV status, and 
those unable to provide informed consent were excluded. 
Following institutional (Durban University o Technology 
Institutional Research EthicsCommittee, IREC 045/14) 
and department of  health (HRKM 234/14) permission, 
written and informed consent was obtained from all par-
ticipants recruited through convenient sampling. Blood 
samples were collected between 10-20 weeks, 22-30 weeks 
and 32-38 weeks via venipuncture in serum separator 
tubes from pregnant women aged 18-45 years, every time 
blood pressure was measured. Clinical and demographic 
variables including maternal age, weight and blood pres-
sure, BMI, parity, HIV status, maternal hemoglobin (Hb) 
levels and birth weight, were derived from chart registers 
and administered epidemiological questionnaires respec-
tively.  HIV status was confirmed at the first antenatal 
visit and if  HIV positive, were immediately placed on 
antiretroviral therapy for prevention of  mother to child 
transmission. Blood samples were centrifuged at 3500 
rpm, 4ºC for 5 min and serum samples were aliquoted 
and stored at -80ºC until analysis. Serum concentrations 
of  sFlt-1 (1:5), sEng (1:5) and PlGF (1:2) were measured 
in triplicate by ELISA according to the manufacturer’s 
protocol (R&D Systems, Minneapolis, MN).
 
Statistical analysis
All statistical analyses were conducted using STATA (ver-
sion 14). Data were assessed for their distribution by the 
Shapiro–Wilk test. The homogeneity of  variance between 
groups was assessed by Levene’s test for equality of  error 
variances. Descriptive statistics was utilized and outcome 
variables are presented as means and median (interquar-
tile range) depending on data distribution. Parity was a 
dichotomous variable evaluated as nulliparous  or mul-
tiparous. BMI was evaluated both as a continuous and 
categorical variable. BMI was dichotomized into ≤ 24.99 
kg/m2 (normal) and >25 kg/m2 (overweight). The Fried-
man’s ANOVA test was used to compare the levels of  
biomarkers stratified by parity, BMI and HIV status. The 
Spearmans rank correlation test was computed to assess 
the relationship between serum levels of  PlGF, sFlt-1 and 
sEng and maternal factors. A probability level of  p < 0.05 
was considered statistically significant.
 
Results
A total of  46 participants were followed at 10-20, 22-30 
and 32-38 weeks’ gestation, respectively. Demograph-
ic and clinical characteristics are presented  in Table 1. 
1823African Health Sciences Vol 19 Issue 2, June, 2019
The mean maternal age at delivery was 25 years, whilst 
the mean birth weight was 3.01 kg.  Of  the total sample, 
28% were nulliparous and 82% were HIV positive. Both 
systolic and diastolic blood pressure increased slight-
ly throughout the defined gestational intervals. Median 
circulating levels of  PlGF, sFlt-1 and sEng throughout 
pregnancy are presented in Table 2. Both PlGF and sFlt-1 
levels increased throughout pregnancy, while soluble en-
doglin dropped around 30 weeks’ gestation and thereafter 
stabilized to its initial levels. In contrast, both the indices 
of  vascular disturbance (sFlt-1/PlGF and sFlt-1+sEng/
PlGF), decreased considerably towards the end of  2nd 
and 3rd trimesters. 
Table 1: Clinical characteristics of maternal cohort with normotensive pregnancies (n=46) 
Maternal Characteristics  
Maternal age at delivery (yrs) (Mean, SD) 25.76 (5.01) 
Smoking (n, %) 2 (4.35) 
Alcohol use (n, %) 4 (8.70) 
Height (cm)(mean, SD) 1.59 (0.57) 
Weight (kg) (median, IQR) 
10-20 weeks 62.60 (60.00-71.00) 
22-30 weeks 68.15 (63.00-74.30) 
32-38 weeks 72 (66.40-80.00) 
Body Mass Index (BMI, kg/m2) (median, IQR) 
10-20 weeks 25.27 (22.74-28.53) 
22-30 weeks 27.15 (23.95-30.52) 
32-38 weeks 28.35 (25.85-32.46) 
Blood pressure (mmHg)(mean, SD) 
Systolic 
10-20 weeks 101.50 (11.05) 
22-30 weeks 108 (10.21) 
32-38 weeks 110 (10.30) 
Diastolic 
10-20 weeks 60 (8.12) 
22-30 weeks 68 (9.22) 
32-38 weeks 70 (14.32) 
Parity (n, %) 
Nulliparous 13 (28.26) 
Primiparous/multiparous 33 (71.74) 
HIV Status (n, %) 
Positive  38 (82.61)       
Negative  8 (17.39)     







Table 2: Serum levels of PlGF, sFlt-1, sEng and antiangiogenic ratios sFlt-1/PlGF; (sFlt-1 + 





Angiogenic factor Antiangiogenic factor Antiangiogenic ratios 
 
PlGF pg/mL sFlt1 pg/mL sEng (ng/ml) sFlt1/PlGF (sFlt1 + sEng)/PlGF 
 10-20 wks 301.52 (201.71) 1169.17 (825.12) 5.08 (1.99) 5.23 (11.3) 22.31(35.02) 
 22-30 wks 642.48 (374.27) 1244.17 (936.42) 3.94 (1.65) 2.20 (2.24) 8.20 (7.42) 
 32-38 wks 713.53 (534.28) 1358.07 (870.87) 5.33 (3.06) 1.81 (2.71) 7.55 (5.89) 
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Median serum levels of  PlGF, sFlt-1 and sEng through-
out pregnancy, stratified by parity and BMI are shown in 
Table 3. There were no statistically significant differences 
noted based on this stratification.  Median PlGF levels 
in multiparous women increased progressively through-
out pregnancy however, in nulliparous women, there was 
an increase in serum PlGF levels between 10-30 weeks 
with a reduction of  130 pg/ml at 32 weeks’ gestation (Ta-
ble 3).  In contrast, sFlt-1 levels dropped between 22-30 
weeks in nulliparous women compared to multiparous 
and thereafter increased.  Likewise, a reduction in sEng 
levels at 22-30 weeks’ gestation was noted amongst the 
nulliparous and multiparous women, which subsequently 
increased at 32 week’s (Table 3).  With regard to the effect 
of  BMI on the angiogenic profiles, PlGF levels increased 
progressively throughout pregnancy, irrespective of  BMI 
< 24.99 or > 25.00 kg/m2. The concentration of  sFlt-1 
increased amongst those who had a BMI < 24.99 kg/
m2 in contrast to those > 25.00 kg/m2.  Levels of  sEng 
however declined  between 22-30 weeks and thereafter 
increased at 32 week’s irrespective of  BMI < 24.99 or > 
25.00 kg/m2 (Table 3). There were no statistically signifi-
cant differences observed based on this stratification.
Table 3: Effect of parity and BMI on angiogenic and antiangiogenic factors stratified by gestational periods in 
normotensive pregnancies (n=46, median, IQR) 
 
Parity  BMI 
Angiogenic Profiles  Nulliparous Multiparous ≤ 24.9 ≥ 25 















     



















     sEng (10 -20 wks) 5.08 (3.97-5.76) 5.08( 4.28-6.72) 5.52 (4.85-6.72) 4.77 (4.10-5.78) 
sEng (22 -30 wks) 4.01(3.54-5.77) 3.85 (3.58-4.79) 4.18 (3.67-5.77) 3.79 (3.54-5.23) 
sEng (32 -38 wks) 5.13(4.10-7.79) 5.33 (4.67-7.14) 5.33 (4.41-6.59) 5.32 (4.63-7.82) 
     sFIt1/PIGF (10-20 wks) 6.94 (3.36-13.46) 4.01 ( 1.36-8.93) 4.63(1.46-8.67) 6.94(2.27-13.86) 
sFIt1/PIGF (22-30 wks) 2 (1.20-3.58) 2.21 (1.86-3.25) 2.00 (1.20-2.49) 2.47(1.58-5.67) 
sFIt1/PIGF (32-38 wks) 1.99 (0.96-2.46) 1.73 (1.04-3.67) 1.81 (1.04-2.46) 1.93(0.90-3.82) 
     (sFIt1+sEng)/PIGF (10-








38 wks) 5.99 (5.80-9.42) 8.16 (7.22-19.69) 7.55(6.56-10.93) 7.77(4.94-41.28) 
*p<0.05 was considered statistically significant 
Medians of  the angiogenic profiles and selected clinical 
parameters, stratified by HIV status, are shown in Table 4. 
The PlGF levels in the HIV+ve group increased through-
out the defined gestational intervals, in comparison to 
thosewho were HIV-ve.  Whilst higher sFlt-1 levels was 
noted in the HIV+ve group during the 10-20 weeks ges-
tational interval compared to to the HIV-ve group, a re-
duction in their expression was observed during the latter 
gestational intervals.   In contrast, sEng levels remained 
somewhat stable, but declined mid-gestation and there-
after stabilized to their initial expression levels (Table 4). 
The indices of  vascular  disturbance (sFlt-1/PlGF and 
sFlt-1+sEng/PlGF), decreased considerably towards the 
end of  the 2nd  and 3rd gestational intervals in both the 
HIV+ve and -ve groups.    However, the sFlt-1+sEng/
PlGF ratio was much higher in the HIV+ve compared 
to the HIV-ve groups only in weeks 22-38.  Additional-
ly, the median hemoglobin levels was slightly higher in 
the HIV-ve group, whilst BMI and birth weight were al-
most similar (Table 4).   Both the systolic and diastolic 
blood pressures were slightly higher in the HIV-ve groups 
throughout the defined gestational intervals compared to 
the HIV+ve groups.
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Table 4: Angiogenic and antiangiogenic factors in normotensive pregnancy 
stratified by HIV status (n = 46) 
  
Clinical characteristics HIV -ve HIV +ve 
PlGF (pg/ml, median, range) 
10-20wks  240.4(162.8) 308.08 (346) 
22-30wks  771.4 (374.27) 608.09 (428.8) 
32-38wks  483.86 (488.25) 721.5 (595.98) 
sFlt-1(pg/ml, median, range) 
10-20wks  819.69 (851.04) 1246.43 (799.57) 
22-30wks  1335.78 (981.01) 1244.14 (935.09) 
32-38wks  1663.97 (505.7) 1230.05 (857.52) 
sEng (ng/ml, median, range) 
10-20wks  5.02 (5.64) 5.08 (1.75) 
22-30wks  3.88 (1.97) 4.01 (1.69) 
32-38wks  5.67 (2.37) 5.32 (3.38) 
sflt/PlGF (median, range) 
10-20wks   4 (3.58) 5.37 (11.3) 
22-30wks  1.58 (2.81) 2.21 (1.39) 
32-38wks  2.69 (2.55) 1.81 (1.5) 
sFlt-1+sEng/PlGF (median, range) 
10-20wks  33.03 (54.54) 22.31 (38.5) 
22-30wks  5.98 (12.5) 8.53 (6.92) 
32-38wks  5.51 (3.09) 8.16 (5.4) 
BMI (kg/m2, mean, SD) 29.26 (3.16) 29.83 (7.32) 
Hemoglobin (g/dL, mean, SD) 11.78 (0.87) 10.63 (1.54) 
Birth weight (kg, mean, SD) 3.16(0.35) 2.98 (0.41) 
Diastolic blood pressure (mmHg) 
10 -20 wks  63(9) 60 (2) 
22 -30 wks  79 (16) 67(8) 
32 - 38 wks  75 (16) 69(12) 
Systolic blood pressure (mmHg) 
10 -20 wks  113 (30) 100 (10) 
22 -30 wks  110(11) 106 (10) 
32 - 38 wks  112 (24) 110 (10) 
*p<0.05 was considered statistically significant 
  
throughout the defined gestational intervals, an inverse 
and significant correlation was observed between systolic 
blood pressure and PlGF and sFlt-1 at 32-38 weeks’ ges-
tation respectively. A statistically significant positive cor-
relation (r = 0.50) was observed between diastolic blood 
pressure and the antiangiogenic ratio (sFlt-1/PlGF) at 
32-38 weeks’ gestation. A weak positive correlation was 
noted between hemaglobin and sFlt-1+sEng/PlGF ratio 
at 32-38 weeks’ gestation.
Correlations between angiogenic profiles and selected 
clinical characteristics at the defined gestational intervals 
are shown in Table 5. Maternal age was positively cor-
related with both indices of  vascular disturbance (sFlt-1/
PlGF and sFlt-1+sEng/PlGF) at 32-38 weeks’ gestation
(p < 0.05). In addition, a significant but negative cor-
relation was noted between sFlt-1 and those with a BMI 
> 25.00 kg/m2 at 10-20 weeks. Despite the minimal in-
crease noted in both systolic and diastolic blood pressure 
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Table 5: Pearson’s correlations between clinical characteristics and 




factor Antiangiogenic factors Antiangiogenic ratios 
 
PlGF sFlt-1 (pg/ml) sEng (ng/ml) sFlt1/PlGF 
(sFlt1 + 
sEng)/PlGF 
            
      Maternal age (years) 
     10-20wks 0,08 -0,29 0,1 -0,37 -0,31 
22-32wks -0,11 -0,09 0,02 -0,07 -0,06 
32-38wks -0,13 0,13 -0,1 0.61* 0.01* 
      BMI (kg/m2) 
       <24.9 
     10-20wks 0,09 -0,02 0,41 -0,43 -0,23 
22-32wks -0,36 -0,31 -0,22 0,19 -0,14 
32-38wks -0,03 0,19 0,41 0,85 0,6 
  >25.00 
     10-20wks 0 -0.47* -0,06 -0,19 0,04 
22-32wks 0,08 -0,25 -0,27 -0,16 0,19 
32-38wks 0,04 -0,2 -0,14 -0,33 0,06 
Blood Pressure (mmHg) 
     Systolic 
     10-20wks 0,07 0,08 0,11 -0,1 -0,09 
22-32wks 0,17 -0,19 -0,12 -0,19 -0,08 
32-38wks -0.38* -0.47* -0,11 0,29 0,34 
Diastolic 
     10-20wks -0,09 0,1 0,03 0,01 -0,03 
22-32wks -0,04 -0,11 0,28 -0,02 0,23 
32-38wks -0,29 0,15 -0,24 0.50* 0,12 
Hemoglobing/dL 
     10-20wks -0,31 0,17 0,14 0,23 0,1 
22-32wks -0,17 -0,17 0,06 0,11 -0,41 
32-38wks -0,01 0,04 -0,21 -0,16 0.02* 
 *p<0.05 was considered statistically significant 
     
 Discussion 
This study demonstrates fluctuating angiogenic and an-
tiangiogenic profiles (PlGF, sFlt-1, sEng, ratios sFlt-
1:PlGF and sFlt-1+sEng/PlGF) at specific gestational 
intervals in a selected group of  normotensive pregnant-
women. The antiangiogenic ratio sFlt-1/PlGF ratio is 
suggestive of  higher sFlt-1 and lower PlGF levels and is 
a recognized predictor of  HDPs such as PE36. Due to 
the growing association between circulating angiogenic 
and  anti-angiogenic factors in HDPs, it is necessary to 
estimate their expressions throughout gestation and their 
link with risk factors even in normotensive pregnancies. 
To our knowledge, this is the first South African study 
to document the angiogenic concentrations at different 
stages of  pregnancy.  We previously reported higher se-
rum levels of  the anti-angiogenic sFlt-1 and soluble en-
doglin in PE pregnancies compared with normotensive 
pregnancies irrespective of  HIV status, however these 
were cross-sectional studies conducted at term prior to 
delivery33,34. 
Our current study investigated the combination of  ma-
ternal risk factors and angiogenic profiles throughout the 
defined gestational intervals and intended to document 
the concentrations of  angiogenic profiles in normoten-
sive pregnancies, in a population that is prone to a high 
HIV antenatal prevalence. It is hoped that the concentra-
tions documented in our study will  assist as a reference 
range against which these angiogenic and anti-angiogenic 
factors may be compared in HIV complicated pregnan-
cies.
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Our data shows that changes in diastolic blood pressure, 
was positively correlated with the maternal anti-angiogen-
ic ratio (sFlt-1/PlGF) at 32-38 weeks’ gestation (Table 5). 
The mean systolic blood pressure measurements were 
inversely correlated with PlGF and sFlt-1levels at 32-38 
weeks’ gestation. Similar angiogenic data was previously 
reported among normotensive pregnancies26,36. Previous 
studies report an increased risk for PE development in 
healthy nulliparous women in response to elevated systol-
ic and diastolic blood pressures28,37.  However, systolic and 
diastolic pressures measured at 13-21 weeks’ gestation in 
pre-eclamptic women with high levels of  sFlt-1 was re-
ported to be similar to those in normal, uncomplicated 
pregnancies36.  This is suggestive of  a healthy vasculature 
amongst a selected group of  participants who were di-
agnosed with PE, indicative that PE development within 
this group occured in response to either increased circu-
lating sFlt-1 levels or increased susceptibility to vascular 
disorders. Thus, it is possible that even slight increases in 
blood pressure during early to mid gestation may result in 
vascular alterations. Variations in sFlt-1 during pregnancy 
in low risk women may be valuable for PE identification 
in those who lack the conventional risk factors.
Our results which demonstrate an increase PlGF and sFlt-
1 around 32-38 weeks’ gestation (Table 2) concur with 
other longitudinal studies19,28,38. However, the increase 
appeared earlier in our study, at weeks 22–30 which con-
curred with Palm and co-workers39, in contrast to other 
studies28,38.  The rising levels might be caused by a relative 
placental ischemia as a result of  increasing myometrial 
tone and uterine contractions at the end of  pregnancy 
in preparation for delivery40. Moreover, it is possible that 
the modest expression of  PlGF during the 10-20 weeks’ 
gestational interval in our study may be attributed to the 
preliminary vasculogenic phases and thereafter progres-
sively increases after 22 weeks’ gestation due to the an-
giogenc switch from branching to nonbranching angio-
genesis13.  The rise in serum sFlt-1 levels observed in our 
study as gestation progresses, is consistent with several 
studies19,39,41.  It is likely that this elevation is due to in-
creasing placental ischemia and oxidative stress occurring 
during pregnancy, indicative of  angiogenic restriction, 
and controlled vascular permeability42, and is corroborat-
ed by others39,43,44.
Our data also suggests a correlation of  maternal age with 
the anti-angiogenic ratio at 32-38 weeks’ gestation, which 
is consistent with Staff  and co-workers27. However, our 
data shows no link between these angiogenic proteins 
with birth weight or hemoglobin levels, indicative that 
the circulating angiogenic alterations may have little or no 
effect on neonatal wellbeing, or that our sample size was 
too small. Nevertheless, our data has shown that hema-
globin levels were lower in the HIV+ve groups in com-
parison to the HIV–ve groups, despite the lack of  sta-
tistical significance. In our study, the mean Hb level was 
11.78 and 10.63 g/dL in HIV negative and positive wom-
en respectively.  Anaemia in pregnancy is defined when 
the hemoglobin level in peripheral blood is < 11 g/dL45, 
classified into mild anemia (10-10.09 g/dL), moderate 
anaemia (7-9.9 g/dL) and severe anaemia (< 7 g/dL)46,47.
Increased haemoglobin levels is shown to be correlated 
with elevated body mass index, primiparity, an increased 
risk of  gestational hypertensive disorders and adverse 
birth outcomes such as low birth weight from third tri-
mester onwards48. In our study, we also identifed lower 
hemaglobin levels in the HIV positive group, suggestive 
of  mild anemia (Table 4).  Recent provision of  HAART 
to pregnant women, irrespective of  their CD4 counts, 
has contributed significantly to the reduction in maternal 
deaths4. While  HAART has the potential to lower the 
prevalence and severity of  anaemia, mitochondrial tox-
icity and irregular reticulocyte counts appear to be com-
mon effects of  zidovudine, which may exacerbate the risk 
of  anemias4. A South African report published in 2014 
indicate no difference in anemia prevalence in those on 
HAART in comparison to those who received zidovu-
dine alone during pregnancy49, but this warrants further 
investigation.
 
A reduction in serum levels of  sFlt-1and sEng in nul-
liparous women between 22-30 week’s gestation, and an 
elevation from 32 weeks onwards was also noted in our 
study.  Despite the lack of  statistical significance, a reduc-
tion in serum sEng levels at 22-30 weeks’ gestation and 
an elevation at 32 weeks’ was observed (Table 2). Nullip-
arous pregnancies are characterized by higher ischemic 
placental environments since their spiral arteries have not 
been formerly remodeled and is therefore identified as a 
risk factor for PE development40,50. It is still unclear why 
angiogenic/anti-angiogenic profiles are higher in nullip-
arous women. It is possible that  the increased hypoxic 
environment increases placental sFlt-1 production40. The 
high anti-angiogenic state observed in our study during 
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the 3rd gestational interval (32-38 weeks) is consistent 
with that reported by Bdolah and co workers51. The raised 
and modified angiogenic profile observed in nulliparous 
pregnant women may be a possible molecular tool that 
rationalizes the epidemiological association between PE 
and nulliparity. Sovio and co-workers also pooled  the 
sFlt-1:PlGF ratio at 36 weeks’ gestation, with maternal 
characteristics, and corroborated its clinical value in ex-
trapolating the risk of  PE development at term in unse-
lected nulliparous women52.
BMI is also believed to be correlated with angiogenic bal-
ance even in uncomplicated pregnancies26,27.  In our study, 
the sFlt-1 levels decreased consistently throughout preg-
nancy amongst those with BMIs > 25 kg/m2, however, 
a significant negative correlation was observed at 10-20 
weeks.  A similar relationship was observed by Mijal and 
co-workers between second trimester circulating sFlt-1 
levels with BMI in normotensive pregnancies20.  Slight 
inconsistencies may prevail, since we pooled our 2nd tri-
mester data into a gestational interval at 10-20 weeks, due 
to late antenatal attendance. Studies comparing BMI at 
the first antenatal consult with first and second trimes-
ter sFlt-1 levels and sFlt-1/PlGF ratio, revealed a positive 
correlation53.
Conclusion
Since circulating concentrations of  angiogenic and an-
ti-angiogenic factors change with gestational age as 
shown in our study and various others19,26,27,54, their inclu-
sion at different gestation levels may expand its clinical 
value.  However, due to the absence of  pre-eclampsia cas-
es in our study, our reference values for these angiogenic 
profiles are not intended for diagnostic use.  The angio-
genic concentrations described in our study may be used 
to explore the role of  these angiogenic profiles in other 
placental-related disorders. Our data suggest that the an-
giogenic profiles during pregnancy may be differential-
ly adjusted based on the varying physiological maternal 
demands. Our study was limited by a small sample size, 
which reduced statistical power to explore associations 
of  clinical interest.  These results should be confirmed in 
larger studies.
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